Physician profile
Anna Platovsky
NPI 1982966222
$7,015.09
in general payments reported to CMS, 2019-2025
34 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $348 · 2021: $466 · 2022: $906 · 2023: $1,229 · 2024: $1,914 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,699 · Education: $136 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,698.76 |
| Education | $135.68 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,068.36 | 2019-2025 | |
| Janssen Biotech, INC. | $919.91 | 2019-2025 | Stelara, Tremfya |
| Ironwood Pharmaceuticals, INC | $538.57 | 2020-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $494.73 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $446.26 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $363.61 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $315.85 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $308.20 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $195.32 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $185.42 | 2020-2024 | Sutab, Suflave |
| Genzyme Corporation | $153.30 | 2022-2024 | |
| Lilly USA, LLC | $117.11 | 2024-2025 | Omvoh, Mounjaro |
| Daiichi Sankyo INC. | $115.39 | 2019-2023 | Injectafer |
| Intercept Pharmaceuticals, INC. | $98.46 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $95.62 | 2022-2024 | Rebyota |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $89.62 | 2024-2025 | Zenpep |
| Celgene Corporation | $88.19 | 2022-2024 | Zeposia |
| Organon LLC | $59.55 | 2023 | Renflexis, Hadlima |
| Madrigal Pharmaceuticals | $41.80 | 2024 | Resmetirom |
| Novo Nordisk INC | $36.39 | 2025 | Wegovy |
| Celltrion USA INC. | $35.49 | 2025 | Vegzelma |
| Capsovision, INC. | $34.25 | 2023-2024 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $29.98 | 2021 | |
| Nestle Healthcare Nutrition INC. | $27.95 | 2022-2023 | |
| Meridian Bioscience INC. | $25.37 | 2024 | |
| Gilead Sciences, INC. | $17.88 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.44 | 2025 | Sutab |
| Endo Pharmaceuticals INC. | $15.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.64 | 2019 | |
| Redhill Biopharma INC. | $14.57 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $13.94 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $13.86 | 2020 | |
| Romark Laboratories, Lc | $13.58 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Platovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.